EDITORIAL SECTION
-
STRATEGY
Smarter Pharma
Quality management systems QMS are the backbone of pharmaceutical manufacturing ensuring safe products
-
RESEARCH DEVELOPMENT
Cytiva Laboratory capsule filters
Our singleuse selfcontained filtration solution
-
CLINICAL TRIALS
Why Clinical Trials Need Digital Endpoints
According Citeline the average success rate for bringing a Phase candidate to market has dropped to an alltime low of just
-
MANUFACTURING
Ensuring Quality and Compliance in Biopharma
Ensuring quality and regulatory compliance in the biopharmaceutical industry is critical to safeguarding product safety and efficacy
-
Information Technology
The Cost of Bad Data
Modern pharmaceutical research generates an unprecedented volume of information Data from genomic sequencing
-
Biopharma
Reimagining Global Biomanufacturing Capacity with Continuous and Modular Systems
Biotechnology is fueling the ongoing expansion of the global market for a broad array of goods
-
EXPERT Talk
Compliance to Competitive Advantage in Pharma Supply
Compliance gets you through an audit Resilience gets medicines to patients on the day something unexpected happens The DSCSAs enhanced requirements took effect November but real interoperability required three more rounds of accommodation phased implementation with the smalldispenser
Advisory Board
KNOWLEDGE BANK
-
Articles
Efficiency in Bioprocessing: Unveiling Upstream and Downstream Operations
Bioprocessing plays a crucial role in the pharmaceutical biotechnology and healthcare industries ensuring the efficient production of biologics vaccines and other biobased products
Clinical Trials: Failures and Challenges on the Path to Treating Alzheimer’s
Alzheimers disease AD is a neurodegenerative disorder with symptoms of memory loss and cognitive disability Typically it begins with mild symptoms that progress to become more severe AD is the th leading cause of death in the United States among people or older In million Americans suffered from AD and this is expected to rise to million by
How to Mitigate Operational Risks in the Pharma Industry?
The operation of the pharmaceutical industry has significant risks with the most probable being operational risks These risks include supply chain interruption regulatory non compliance product defects technological disruption The development of strategies to avoid compromise in operations remains paramount not only in protecting the customers from harm or receiving
Real-World Evidence in Pharmaceutical Drug Development
For most of the past halfcentury the randomised controlled trial has been the undisputed gatekeeper of pharmaceutical value It remains the gold standard for establishing causality and nothing in this article suggests otherwise Yet the controlled trial answers a narrow question under artificial conditions does a drug work in a carefully selected population managed by expert investigators over a fix...
Access to Affordable Medicines: A Persistent Challenge for Europe
The problem of affordable medicines has been topical in Europe for many years Despite the fact that there are well developed health units in many regions of the world and particularly in this continent the health challenges of the population have not been fully met especially in access to affordable basic medicines This problem is relevant not only to the patients but also to the stability of heal...
From Static PDFs to Usable Digital Forms in Pharmaceutical Operations
Walk through the quality compliance or operations function of almost any pharmaceutical manufacturer and youll find PDF forms everywhere from deviation reports change controls and training records to supplier questionnaires audit checklists and equipment logs Many of these documents exist as PDF files but functionally still behave like paper Someone prints them fills them in by hand
-
Techno Trends
Alume Biosciences Secures FDA Breakthrough Therapy Designation for Bevonescein
Alume Biosciences has received Breakthrough Therapy Designation BTD from the US Food and Drug Administration FDA for bevonescein an investigational fluorescent drug being developed to support realtime nerve visualisation during head and neck surgery in adults Bevonescein is an intravenous fluorescent peptidedye conjugate that binds to nerve tissue
-
Projects
SK pharmteco Plans More Than US$200 Million Investment in Small Molecule and Peptide Manufacturing
SK pharmteco is planning a fiveyear investment of more than US million to expand and modernise its pharmaceutical development and manufacturing operations in the United States The programme will strengthen capabilities for small molecules and peptides while supporting a more
-
Research Insights
A drug repurposing screen reveals dopamine signaling as a candidate therapeutic pathway for PIGA-CDG
PIGACDG is a congenital disorder of glycosylation caused by pathogenic partial lossoffunction variants in the PIGA gene PIGA encodes an enzyme responsible for the catalytic transfer of Nacetylglucosamine
-
whitepaper
Post-Translational Modifications in Drug Discovery: From Molecular Regulation to Clinical Impact
For decades the central dogma of molecular biology has anchored our understanding of cellular function DNA to RNA to protein But this linear view is incomplete A growing body of evidence shows that much of biologys
TOP ARTICLES
-
1
Clinical Trials: Failures and Challenges on the Path to Treating Alzheimer’s
Ronny Priefer
Jinwoo Lee
This year marks the 30th anniversary of the approval of tacrine, the first drug targeting Alzheimer’s disease. Although not a curative agent, it provided some assistance to those afflicted with...
-
2
How to Mitigate Operational Risks in the Pharma Industry?
Kate Williamson
This article also considers the possible solutions and recommendations for organizations which planning to minimize the operational risks as for the general field and in the context of pharmaceuticals...
-
3
Real-World Evidence in Pharmaceutical Drug Development
Lakshmi
Real-world evidence has moved from post-marketing footnote to strategic currency in pharmaceutical drug development. With regulators on both sides of the Atlantic now accepting registry, claims and he...
-
4
Access to Affordable Medicines: A Persistent Challenge for Europe
Kate Williamson
High accessibility to medicines is still a concern in Europe due to increasing costs and variability in price per country and a lack of legislation to mitigate the problem. The problem of high prices...
-
5
From Static PDFs to Usable Digital Forms in Pharmaceutical Operations
Emily Shaw
Pharmaceutical operations continue to rely heavily on PDF-based documentation across quality, compliance and manufacturing processes. However, static PDFs can introduce manual data-entry, validation,...
press releases Read more...
Cardiff Oncology Receives FDA Orphan Drug Designation for Onvansertib in Chronic Myelomonocytic Leukemia
Cardiff Oncology Inc a clinicalstage biotechnology company leveraging PLK inhibition to develop novel cancer therapies today announced that the US Food and Drug Administration FDA has granted Orphan Drug Designation to onvansertib for the treatment of patients with chronic myelomonocytic leukemia
Geneos Therapeutics Initiates IMPACT31 Phase 2 Randomized Clinical Trial Evaluating Neoantigen-Targeted Personalized DNA Immunotherapy for Cancer
Geneos Therapeutics a clinical stage biotherapeutics company focused on the development of neoantigenbased personalized immunotherapy for cancer PIC today announced the initiation of its Phase randomized clinical trial NCT in patients with highrisk hepatocellular carcinoma HCC liver cancer
Medicovestor Announces FDA Fast Track Designation for MC001, Its First-in-Class Chemoimmunotherapy ADC for Pancreatic Cancer
Medicovestor Inc today announced that the US Food and Drug Administration FDA has granted Fast Track designation to MC its lead investigational firstinclass chemoimmunotherapy antibodydrugconjugate ADC for pancreatic cancer
Orogen Therapeutics Announces Selection of Two Development Candidates for Immune Diseases, Potential Best-in-Class Oral IL-17 and JAK1/TYK2 Small Molecule Inhibitors
Orogen Therapeutics Inc announced the selection of two development candidates DCs ORO and ORO potential bestinclass oral small molecule inhibitors of IL and JAKTYK respectively Both DCs have completed extensive nonclinical studies to demonstrate attractive
Events Read more...
21 - 23
Oct 2026Drug Formulation & Drug Delivery 2026
Paris, France
21 - 22
Oct 2026Advance Clinical Trials and Research 2026
Paris, France
22 - 23
Oct 2026PDA Aseptic Symposium 2026
Congress Square Nakanoshima, O...
26 - 28
Oct 2026ACHEMA Middle East 2026
RICEC, Riyadh, KSA, Saudi Arab...
26 - 28
Oct 2026World Orphan Drug Congress
RAI, Amsterdam, Netherlands
27 - 28
Oct 2026Pharma Manufacturing & Automation Convention 2026
Novotel Hyderabad Airport, Ind...
28 - 30
Oct 2026BIOPLUS-INTERPHEX KOREA 2026
COEX, Seoul
02 - 04
Nov 2026Pharma Forum EMEA 2026
Dom Pedro Lisboa Hotel, Lisbon...
LATEST NEWS Read more...
AI Proteins Announces Research Collaboration and License Agreement With Astellas Pharma to Discover and Develop Novel Miniprotein-Based Therapeutics Valued at Over $400 Million
AI Proteins Inc a biotechnology company that utilizes computational de novo protein design to create therapeutic miniproteins today announced it has entered into a Research Collaboration and License Agreement with Astellas Innovation Management LLC an affiliate of Astellas Pharma Inc TSE to discove...
Okomera Announces Trade Agreement with Servier to Use Tumor Miniaturization Technology in Cancer Research
Okomera a TechBio company that personalizes cancer management with its technology combining minivatars tumor microfluidics and AI imaging today announced the signing of a commercial agreement with Servier an independent international pharmaceutical group
ScionxBio Announces Collaboration to Develop Long-Acting xRNA Therapeutics
ScionxBio a privately held preclinicalstage biotechnology company pioneering nextgeneration mRNA therapeutics distinguished by their extended durability profile today announced that it has entered into a worldwide strategic collaboration and licensing agreement with Sanofi
Takara Bio USA Partners with SPT Labtech to Deliver Automation-Ready NGS Library Preparation Technologies
Takara Bio USA Inc a wholly owned subsidiary of Takara Bio Inc and SPT Labtech today announced their partnership to deliver validated automated library preparation workflows that combine Takara Bio nextgeneration sequencing NGS library preparation chemistries with SPT Labtechs firefly liquid handlin...
AtomVie Global Radiopharma Announces Strategic Partnership with Jubilant Radiopharma to Strengthen Logistics and Distribution in Clinical Trials
AtomVie Global Radiopharma a global contract developer and manufacturer CDMO for radiopharmaceuticals today announced a strategic partnership with Jubilant DraxImage Inc operating as Jubilant Radiopharma Jubilant Radiopharma to provide logistics approval and lastmile distribution services to support
Transcripta Bio Announces Research Collaboration to Advance Discovery of New ALS Treatments
Transcripta Bio an AIpowered drug discovery company focused on neurological and neuromuscular diseases today announced a research collaboration and licensing agreement with Mayo Clinic centered on amyotrophic lateral sclerosis ALS a fatal neurodegenerative disease with few effective treatments





